

FORM 13-501F2
CLASS 2 REPORTING ISSUERS – PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, Sabino Di Paola, an officer of the reporting issuer noted below have examined this Form 13-501F2 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

Name: Sabino Di Paola
Title: CFO

Date: March 21, 2017

Reporting Issuer Name:

Tetra Bio-Pharma Inc

End date of previous financial year:

Nov 30, 2015

Financial Statement Values:

(Use stated values from the audited financial statements of the reporting issuer as of the end of its previous financial year)

Retained earnings or deficit

\$ (958,600) (A)

Contributed surplus

\$ 116,537 (B)

Share capital or owners' equity, options, warrants and preferred shares (whether such shares are classified as debt or equity for financial reporting purposes)

\$ 611,871 (C)

Non-current borrowings (including the current portion)

\$ 0 (D)

Finance leases (including the current portion)

\$ 0 (E)

Non-controlling interest

\$ 0 (F)

Items classified on the statement of financial position as non-current liabilities (and not otherwise listed above)

\$ 0 (G)

Any other item forming part of equity and not set out specifically above

\$ 0 (H)

Capitalization for the previous financial year
(Add items (A) through (H))

\$ (230,220)

Participation Fee

\$ 400

Late Fee, if applicable

\$ 0

Total Fee Payable
(Participation Fee plus Late Fee)

\$ 400